GSK, Amira sign $425M licensing pact

GlaxoSmithKline has agreed to pay Amira Pharmaceuticals up to $425 million for the exclusive worldwide rights to its FLAP inhibitors, including AM103 and other compounds within the current development program. Glaxo will first focus on AM103, an experimental asthma therapy that has successfully completed a Phase I trial. 

"With their experience and expertise in this area we hope that AM103 will become the first FLAP inhibitor available to patients worldwide to treat symptoms of asthma and possibly other inflammatory diseases," says Peppi Prasit, CSO and co-founder of Amira.

- check out the release for more info

Related Articles:
GSK shakes up R&D. Report
Behind the scenes of GSK's overhaul. Report